ArticlePloS one2026
Epidemiology of invasive pneumococcal disease in Southwest Sweden during the first eleven years after the introduction of general childhood pneumococcal vaccination.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive pneumococcal disease (IPD) still causes significant morbidity and mortality. In this study, we describe incidence, risk factors, manifestations, and outcome of IPD in Southwest Sweden during the first eleven years after the introduction of conjugate pneumococcal vaccines in the childhood vaccination program in 2009.
methodsClinical data from 2,288 consecutive episodes of IPD in Region Västra Götaland, Sweden during 2009-2019 were retrospectively collected from medical records. Incidence rates were calculated using population data from the same period. The results were compared to data from three previous studies from the same geographical area with a total follow-up of 56 years.
resultsThe incidence of all IPD episodes in 2009-2019 was 12.8/100,000/year. A very high IPD incidence was seen in patients with multiple myeloma (1,497/100,000) and chronic lymphocytic leukemia (505/100,000). Meningitis occurred in 26% of the IPD episodes in children <2 years compared to 4.3% in the age group ≥65 years (12/46 versus 60/1,403; p < 0.001). The opposite was found for pneumonia, which accounted for 22% of the IPD episodes in children <2 years compared to 77% among the elderly (10/46 vs. 1,085/1,403; p < 0.001). In 604 IPD episodes (26.4%), one or more complications were observed, most commonly parapneumonic effusion and empyema. When data were compared with the previous study period, the IPD incidence in children <2 years declined from 22.5 in 1996-2008 to 10.7 per 100,000 in 2009-2019, while only a modest reduction was observed in adults ≥65 years (from 45.0/100,000 to 41.2/100,000). The overall case fatality rate (CFR) increased from 9.9% in 1996-2008 to 12.9% in 2009-2019, which could be explained by increased patient age and underlying comorbidity.
conclusionsA substantial decrease in IPD incidence was seen in infants and young children but not in the elderly during the first eleven years after the introduction of the general childhood pneumococcal vaccination program. Patients with hematological malignancies remain a high-risk group of IPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.